trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Blood thinners stop the creation of platelets

the verdict
REFUTED
the evidence says no
Recorded sources
0 sources for · 4 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Blood thinners do not stop the creation of platelets; rather, they typically function by inhibiting coagulation factors (such as thrombin or factor Xa) or by preventing existing platelets from aggregating.

The analysis

The claim is specific and empirical, therefore passing Step 0. However, the scientific mechanism of 'blood thinners' (anticoagulants and antiplatelets) involves inhibiting clotting factors or platelet aggregation/activation, not stopping the biological creation (thrombopoiesis) of platelets in the bone marrow. The retrieved literature discusses anticoagulants targeting coagulation cascades and separate antiplatelet mechanisms, directly refuting the idea that they stop platelet creation.

Evidence against · 4
Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation.
Recorded source metadata

A Gårde, K Samuelsson, H Fahlgren, E Hedberg, L G Hjerne, J Ostman. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation.. 1983. https://doi.org/10.1161/01.str.14.5.677

This study compares anticoagulants with agents that inhibit platelet aggregation, distinguishing between the coagulation cascade and platelet function.

See more details
More against · 3
Inhibition of factor Xa activity, platelet aggregation, and experimentally induced thrombosis by Sparstolonin B.
Recorded source metadata

Nayeon Kim, CheLynn Jeon, Chaeyeong Kim, Soo Ho Ryu, Wonhwa Lee, J. Bae. Inhibition of factor Xa activity, platelet aggregation, and experimentally induced thrombosis by Sparstolonin B.. 2022. https://doi.org/10.1016/j.phymed.2022.153987

This paper evaluates an agent that targets both factor Xa and platelet aggregation pathways separately rather than suggesting blood thinners stop platelet creation.

Anticoagulant Effects of Albiflorin via Factor Xa Inhibition.
Recorded source metadata

Du XX, Jeong YH, Han G, Bae JS. Anticoagulant Effects of Albiflorin via Factor Xa Inhibition.. 2026. https://doi.org/10.1177/1096620x261422285

The study highlights that the agent acts as a direct factor Xa inhibitor while also separately assessing its effects on platelet aggregation.

Anti-Thrombotic Activities of Veratramine via Inhibiting Platelet Aggregation and FIIa/FXa.
Recorded source metadata

Han G, Kim GE, Park DH, Bae JS. Anti-Thrombotic Activities of Veratramine via Inhibiting Platelet Aggregation and FIIa/FXa.. 2026. https://doi.org/10.3390/biology15060462

This research shows that the investigated compound exhibits direct dual inhibition of clotting factors alongside the suppression of platelet reactivity and aggregation.

The paper trail · every fact has a biography
first checked02 Aug 2026
judged → REFUTED · 1002 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.
trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt